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Summary
The data presented in this paper describe trends in treated problem opiate use in 
Ireland between 2002 and 2007. The paper describes treated problem opiate use in 
relation to person, place and time. The analysis presented is based on data reported to 
the National Drug Treatment Reporting System (NDTRS). It is important to note that 
the NDTRS collects data on episodes of treatment in a calendar year, rather than on 
the individual person treated. This means that individuals may appear in the figures 
more than once if they receive treatment at more than one centre, or at the same 
centre more than once per year. 
The main findings and their implications are:
In 2007, 11,538 cases were treated for problem opiate use, of whom 66% were cases 
continuing in methadone treatment from the preceding calendar year and carried 
forward on 1 January 2007. The number of cases carried forward increased by 36% in 
the reporting period. During the lifetime of the National Drugs Strategy (2001–2007), 
an additional 2,680 methadone places were created, which represents an increase in 
places of 54%.
The number of opiate cases entering treatment increased by 22%, from 3,202 in 2002 
to 3,895 in 2007. The number of previously treated cases increased by 15%, from 
2,252 in 2002 to 2,598 in 2007, while the number of new cases increased by 42%, 
from 809 in 2002 to 1,151 in 2007. The increase in numbers could be explained by 
an increase in problematic opiate use in the population, an increase in the number of 
service providers reporting treated cases to the NDTRS, an increase in the provision of 
opiate services, or, most likely, a combination of these three factors. 
The number of cases who reported opiates as their main problem substance, 
increased by 16%, from 3,077 in 2002 to 3,575 in 2007. The number of cases who 
reported opiates as an additional problem substance increased by 6%, from 713 
in 2002 to 757 in 2007.
Contents
Summary 1
Glossary 4
Introduction 6
Methods 8
Analysis 9
Conclusions 29
References 30
Acknowledgements 32
2 HRB Trends Series 7
The prevalence of treated problem opiate use among 15–64-year-olds living in Ireland increased by 
15%, from 326 per 100,000 in 2002 to 376 in 2007. This indicates that problem opiate use is a recurring 
addiction that requires repeated episodes of treatment over time. 
The incidence of treated problem opiate use among 15–64-year-olds living in Ireland increased by 22%, 
from 28 per 100,000 in 2002 to 35 in 2007. 
The incidence of cases treated for opiates as their main problem substance between 2002 and 2007 was 
examined by place of residence. While the incidence of such cases living in Dublin decreased by 19% over 
the six-year period, the incidence of cases living outside Dublin increased by 126%. 
The data on heroin users treated for the first time indicate that the highest numbers and rates were in 
Dublin, but that heroin use had spread to every county in Ireland, with a steady increase in numbers in 
counties in the midlands, the north-east and the south-east. The numbers of new cases entering treatment 
are an indirect indicator of recent trends in problem drug use.
In 2007 the majority (75%) of opiate cases were treated in outpatient services. During the period under 
review, increasing numbers and proportions were treated in inpatient services each year. Of the 3,575 
cases entering treatment in 2007 who reported opiates as their main problem substance, 53% received 
counselling, 46% commenced methadone maintenance, 23% received a brief intervention, and 10% 
commenced a medically assisted opiate detoxification. Over 46% of cases received more than one initial 
treatment intervention. It is widely recognised that a combination of interventions is required to effectively 
treat problem opiate use.
Of the 20,155 opiate cases who entered treatment in the years 2002–2007, the majority, 19,105 (95%), 
used heroin, 3,519 (17%) used either prescribed (509) or street (3,010) methadone, and 898 (4%) used 
other opiates, including unspecified opiates and analgesics containing an opiate compound. Of those 
entering treatment for problem methadone use in 2007, the majority (87%) used street methadone and 
13% used prescribed methadone. The cases using prescribed methadone were entering a detoxification 
facility after a period on methadone substitution. 
The proportion of cases who reported an opiate as their main problem substance and who used more 
than one substance decreased from 69% in 2002 to 63% in 2007. The decrease in polysubstance use was 
observed among both new and previously treated opiate cases, but was more marked among the new 
cases. Cannabis, benzodiazepines and, in more recent years, cocaine were the most common additional 
problem substances reported by opiate cases entering treatment between 2002 and 2007. Polysubstance 
use increases the complexity of these cases, and is associated with poorer treatment outcomes.
In 2007 the main problem substances associated with opiates as an additional problem substance were 
other opiates (56%) and, to a lesser extent, alcohol (16%) and cocaine (12%). Use of any one of these 
substances can lead to severe dependence; when two or more are used, it is often difficult for the service 
provider and the client to establish which is the main problem substance. 
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Among new opiate cases in the six-year period, the median age at first use of any drug was 15 years, and 
the median age at first use of opiates was 19 years. This finding indicates that opiates were unlikely to 
be among the first drugs used by these cases, and that they used one or more opiates for a considerable 
period before seeking treatment. The median age at which new opiate cases commenced injecting was 
20 years. In the interval between commencing opiate use and seeking treatment, a significant minority of 
users change from smoking to injecting opiates, and may subsequently contract a blood-borne virus such 
as hepatitis C. Half of the new opiate cases had been using opiates for five years or more before seeking 
treatment. The pattern of opiate use evidenced by these findings points to the need to bring opiate users 
into treatment earlier.
In 2007, of the 3,575 cases who entered treatment and reported opiates as their main problem 
substance, 52% smoked it, 40% injected it, and 5% consumed it orally. Between 2003 and 2007, 
decreasing proportions of cases reported that injecting was their primary route of administration, while 
correspondingly increasing proportions reported smoking opiates. Among cases living in Dublin, injecting 
decreased by 29% and smoking increased by 9%. This trend was even more evident in cases living outside 
Dublin, where smoking overtook injecting at a much faster rate, rising by 230% over the six-year period. 
This is a positive finding, indicating that opiate users are heeding the advice contained in harm reduction 
messages. 
In 2007, of the 3,575 cases who entered treatment and reported opiates as their main problem substance, 
54% used it daily, 10% used it on two to six days per week, 6% used it once per week or less and 25% 
had not used it in the month prior to entering treatment. The proportion of daily users was much higher 
among new cases (70%) than among previously treated cases (48%). There was a 26% increase in the 
proportion of cases reporting daily use of opiates during the reporting period; the largest increase was 
among new cases, where daily use increased by 36%. The high proportion of previously treated cases who 
had not used an opiate in the month prior to treatment is explained by the transfer of stable clients to the 
services of general practitioners and to detoxification centres.
The median age of previously treated cases entering treatment for opiates as their main problem substance 
increased from 26 to 29 years between 2002 and 2007. In 2007 almost 3% of new cases were under 18 
years of age, while less than 1% of previously treated cases were in this age group. The proportion of new 
cases aged under 18 years increased between 2006 and 2007, which reflects the increase in adolescent 
treatment services and their compliance with the NDTRS. In 2007, 73% of cases entering treatment for 
opiates as their main problem substance were male; only 13% were employed, a considerable fall from the 
2002 figure of 21%. In 2007, the proportion of opiate cases who reported leaving school early was higher 
among previously treated cases (26%) than among new cases (21%). During the period under review, very 
few opiate cases aged under 18 reported that they were still at school. An average of one in twenty opiate 
cases entering treatment reported being homeless. The socio-economic profile of treated opiate users is one 
of low educational levels and limited economic opportunity. It is clear that programmes to address problem 
opiate use must include strategies that redress disadvantage.
4 HRB Trends Series 7
Glossary
Opiates•  are powerful drugs derived from the opium poppy plant and have been used for centuries 
to relieve pain. They include opium, heroin, morphine, and codeine. Some opiates, such as morphine 
and codeine, are used in the treatment of pain related to illness (for example, cancer) and in medical 
and dental procedures. When used as prescribed by a medical doctor, opiates are safe and generally 
do not lead to dependence. When misused, opiates possess very strong reinforcing properties and 
can quickly trigger addiction.
Heroin•  is a synthetic opiate that is highly addictive. It is made from morphine, which is a naturally 
occurring opiate extracted from the seed pod of the Asian opium poppy plant. Heroin can take the 
form of a white or brown powder or a black sticky substance known as ’black tar heroin’. Heroin 
enters the brain, where it is converted to morphine, which then binds to opioid receptors in the 
body, especially those involved in the perception of pain and reward. With regular heroin use, 
tolerance develops. This means that more heroin is required to achieve the same intensity of effect. 
Eventually, chemical changes in the brain can lead to addiction.
Methadone•  is a synthetic opiate that binds to the same receptors in the brain as heroin does. It has 
been used for more than 30 years to treat heroin addiction. When taken orally, as per prescription, it 
has a gradual onset of action and sustained effects, reducing the desire for other opioid drugs while 
preventing withdrawal symptoms. Properly prescribed methadone is not intoxicating or sedating, 
and its effects do not interfere with ordinary daily activities. In the majority of cases methadone is a 
stabilising factor that permits heroin users to change their behavior and to discontinue heroin use. 
Methadone that is diverted from opiate users in treatment programmes to opiate users who are not 
in treatment is categorised as street methadone. 
The • median is the value at the mid–point in a sequence of numerical values ranged in ascending or 
descending order. It is defined as the value above or below which half of the values lie. Unlike the 
mean (average), the median is not influenced by extreme values (or outliers). For example, in the 
case of five drug users aged 22, 23, 24, 24 and 46 years respectively, the median (middle value) is 
24 years, whereas the mean is 27.8 years. While both the median and the mean describe the central 
value of the data, the median is more useful in this case because the mean is influenced by the one 
older person in this example. 
Incidence•  is the number of new cases of disease or events that develop among a population during 
a specified time interval. As an example, in 2007, in a county with a population of 31,182, 10 opiate 
users sought treatment for the first time. The incidence is the number of new cases treated divided 
by the county population, expressed per given number of the population, i.e., per 100, per 1,000, 
per 10,000, per 100,000 etc. 
The rate in this example may be calculated as follows: (10/31,182) x 100,000, which gives an 
incidence rate of 32 per 100,000 of the county population in 2007.
Prevalence•  is the proportion of people in a population who have a disease or condition at a specific 
point or period in time. As an example, in 2007, in a county with a population of 31,182, 10 opiate 
users sought treatment for the first time, 20 returned to treatment and five continued in treatment 
from the previous year, giving a total of 35 people treated for problem opiate use in the year. The 
prevalence is the total number of cases divided by the county population, expressed per given 
number of the population, i.e., per 100, per 1,000, per 10,000, per 100,000 etc. 
The rate in this example may be calculated as follows: (35/31,182) x 100,000, which gives a 
prevalence rate of 112 per 100,000 of the county population in 2007.
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Epidemic•  disease levels exist when there is an excess number of new cases among a specific 
population for that point and place in time. An epidemic can also be called an outbreak. An excess 
number of cases is defined as a number greater than two standard deviations above the norm 
expected for that point in time.
Health Service Executive (HSE)
On 1 January 2005, the 10 health boards managing the health services in Ireland were replaced  –
by a single entity, the Health Service Executive (HSE). The former health boards were responsible 
for health care provision to populations in specific geographical areas. In the interest of continuity 
of care, the HSE maintained these 10 areas for an interim period and called them HSE areas. The 
former Eastern Regional Health Authority was known as the HSE Eastern Region for this interim 
period. 
The table below presents the past health board structure and the interim HSE areas structure: –
Regional Health Authority Health boards HSE areas
Not applicable North Eastern Health Board HSE North Eastern Area
Eastern Regional Health Authority (ERHA*) Northern Area Health Board HSE Northern Area
Eastern Regional Health Authority (ERHA) East Coast Area Health Board HSE East Coast Area
Eastern Regional Health Authority (ERHA) South Western Area Health Board HSE South Western Area
Not applicable Midland Health Board HSE Midland Area
Not applicable South Eastern Health Board HSE South Eastern Area
Not applicable Southern Health Board HSE Southern Area
Not applicable Mid–Western Health Board HSE Mid-Western Area
Not applicable North Western Health Board HSE North Western Area
Not applicable Western Health Board HSE Western Area
*The ERHA was known as the HSE Eastern Region for the interim period
Following a number of years of re-structuring, health care is now provided through four HSE  –
regions and 32 local health offices (LHOs). The local health offices are based on the geographical 
boundaries of the former community care areas. The table below presents the current HSE 
structure:
HSE regions Local health offices
HSE Dublin 
North East 
North West Dublin
North Central Dublin
North Dublin
Cavan/Monaghan
Louth
Meath
HSE Dublin 
Mid-Leinster 
Dublin South
Dublin South East
Dublin South City
Dublin South West
Dublin West
Kildare/West Wicklow
Wicklow
Longford/Westmeath
Laois/Offaly
HSE South 
Cork South Lee
Cork North Lee
West Cork
North Cork
Kerry
Carlow/Kilkenny
Tipperary South 
Waterford
Wexford
HSE West 
Donegal
Sligo/Leitrim/West Cavan
Galway
Mayo
Roscommon
Tipperary North/East Limerick
Limerick
Clare
The data in this paper relating to the average annual incidence of treated problem substance use and place 
of residence of treated cases living in Ireland are presented by HSE region and by former health board 
area. Each of the four HSE regions is made up of a number of former health board areas and can be easily 
divided along their boundaries. It is also worth noting that the 10 regional drugs task forces were created to 
service the areas covered by the former health boards.
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Introduction
The National Drug Treatment Reporting System (NDTRS) is an epidemiological database on treated drug 
and alcohol misuse in Ireland. It is co-ordinated by staff at the Alcohol and Drug Research Unit (ADRU) 
of the Health Research Board (HRB) on behalf of the Department of Health and Children. The monitoring 
role of the NDTRS is recognised by the Government in its document Building on experience: National Drugs 
Strategy 2001–2008. The collection and reporting of data to the NDTRS is one of the actions identified and 
agreed by Government for implementation by the former health boards (now HSE regions): ‘All treatment 
providers should co-operate in returning information on problem drug use to the Drug Misuse Research 
Division [now ADRU] of the HRB’ (Department of Tourism, Sport and Recreation 2001: 118). 
The NDTRS was established in 1990 in the Greater Dublin Area and was extended in 1995 to cover all 
areas of the country. It was developed in line with the Pompidou Group’s Definitive Protocol (Hartnoll 
1994) and subsequently refined in accordance with the Treatment Demand Indicator Protocol (EMCDDA 
and Pompidou Group 2000). Originally designed to record drug misuse, the NDTRS recorded problematic 
use of alcohol only in cases where it was an additional problem substance, that is, where the client’s 
main reason for entering treatment was drug misuse but he/she also reported problematic use of alcohol. 
However, it became increasingly evident that alcohol was the main problem substance in Ireland and 
that a large proportion of cases used both alcohol and drugs (Long et al. 2004). In parts of the country, 
particularly outside Dublin, alcohol and drug treatment services are integrated. Failure to include alcohol 
data in reporting systems leads to an underestimation of problem substance use, and of the workload of 
addiction services (Long et al. 2004). In recognition of this, the remit of the NDTRS was extended in 2004 
to include cases where alcohol is recorded as the main or only reason for seeking treatment. The overlap 
between problem alcohol use and problem drug use has been identified in the current strategic plans of a 
number of drugs task forces, which have emphasised the need for treatment services that can address the 
many forms of polysubstance use.
Drug and alcohol treatment data are viewed as an indirect indicator of drug and alcohol misuse, as well 
as a direct indicator of demand for treatment services. NDTRS data are used at national level (alcohol 
and drug data) and at European level (drug data) to provide information on the characteristics of clients 
entering treatment and on patterns of substance misuse, such as types of substance used and consumption 
behaviours. Drug data are ‘valuable from a public health perspective to assess needs, … and to plan and 
evaluate services’ (EMCDDA 1998: 23). 
Information from the NDTRS is made available to service providers and policy makers and is used to inform 
local and national substance misuse policy and planning. In 1996, NDTRS data were used to identify a 
number of local areas with problematic heroin use (Ministerial Task Force 1996). These areas were later 
designated as Local Drugs Task Force (LDTF) areas, and are continuing to co-ordinate strategic responses 
to drug misuse in their communities. Again, in 2004, NDTRS data were used to describe treatment-seeking 
characteristics and behaviours of those under 18 years and to inform the deliberations of the Working 
Group on the need for a specific treatment approach (Working Group on treatment of under 18 year 
olds 2005). In recent years, NDTRS data have been used to inform some of the recommendations of the 
Working Group on Drugs Rehabilitation (2007), and by the Working Group on residential services to help 
estimate the number of residential places required to address severe alcohol and drug problems in Ireland 
(Corrigan and O’Gorman 2007). The Comptroller and Auditor General (2009) used data from the reporting 
system in a special report which examined treatment and rehabilitation services provided for people with 
drug addictions. 
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The National Advisory Committee on Drugs (NACD) commissioned a report estimating the prevalence of 
opiate use in Ireland as a whole, in Dublin, and in the rest of Ireland for the years 2000 and 2001 (Kelly et 
al. 2003). In 2001 it was estimated that there were between 13,405 and 15,819 people aged 15–64 years 
using opiates in Ireland. Opiate use was predominantly a Dublin phenomenon, with a rate of 16 cases per 
1,000; outside Dublin the rate was just under 1 per 1,000. The NACD is currently calculating an estimate of 
problem opiate users in Ireland in 2006. 
Table 1 Estimated prevalence of opiate use among the 15–64-year-old population in Ireland, 
in Dublin, and in the rest of Ireland, 2000 and 2001
2000 2001
Estimate
Lower 
bound
Upper 
bound
Rate/1000 
population
Estimate
Lower 
bound
Upper 
bound
Rate/1000 
population
Ireland 14,158 12,884 15,883 5.6 14,452 13,405 15,819 5.6
Dublin 12,268 11,204 13,725 16.1 12,456 11,519 13,711 16.0
Rest of 
Ireland 2,526 1,893 3,639 1.0 2,225 1,934 2,625 0.9
Source: Kelly et al. 2003
The number of heroin seizures increased by 105%, from 612 in 2004 to 1,698 in 2007 (CSO 2009).
According to the National Drug-Related Deaths Index, 1,553 deaths by poisoning were recorded between 
1998 and 2005, of which 714 were attributed to a single substance and 839 were attributed to two or 
more substances (Lyons et al. 2008). Of the 714 cases of death due to a single substance, heroin and 
unspecified opiates accounted for 22% (159), analgesics containing an opiate compound accounted for 
almost 12% (85) and methadone alone accounted for a further 9% (61). Of the 839 polysubstance deaths, 
46% (388) involved an opiate (mainly heroin and/or methadone) in conjunction with at least one other 
substance. A further 21% (177) involved substances which included an analgesic containing an opiate 
compound.
The number of poisoning deaths in which opiates were implicated, alone or with another drug, increased 
steadily from 111 in 1998 to 146 in 2005. In that eight-year period, heroin was recorded as one of 
the drugs implicated in 19.8% of deaths by poisoning; methadone was implicated in 19.4% of those 
deaths, and other opiates (including analgesics containing an opiate compound) in 23.3%. Heroin and/or 
methadone were often associated with benzodiazepine or cocaine in cases of polysubstance poisoning. 
In 2008 the NACD published ROSIE Findings 7, a summary of opiate treatment outcomes at one year and 
at three years after entry into treatment (Comiskey et al. 2008). The ROSIE (Research Outcome Study in 
Ireland) study is the first national longitudinal multi-site drug treatment outcome study in Ireland. The 
404 opiate users recruited to the study were entering treatment for the first time, or were returning to 
treatment after a period of absence. The study followed participants from the point of commencing a new 
treatment episode and monitored their progress at one-year and three-year intervals. 
The main results summarised in ROSIE Findings 7 included the following:
The proportion of participants who reported using heroin in the 90 days preceding data collection • 
fell from 81% at intake to 47% at one year, and this decrease was sustained at three years.
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There were reductions in the proportions who reported use of non-prescribed methadone, cocaine • 
powder, crack cocaine, cannabis, alcohol and non-prescribed benzodiazepines at one year after 
treatment intake. The reduced levels were maintained between one-year and three-year follow-up for 
all drugs except benzodiazepines. 
The proportion who reported use of more than one drug decreased from 78% at intake to 50% one • 
year later and to 45% three years following intake. The proportion who reported injecting drug use 
in the 90 days preceding data collection decreased from 46% at intake to 29% at one year and 27% 
at three years. 
The largest achievements between one and three years were in the areas of housing, training and • 
employment. The proportion who reported involvement in acquisitive crime decreased from 31% at 
intake to 14% at one year and this decrease was sustained at three years. In addition, the proportion 
who reported selling or supplying drugs reduced from 31% at intake to 11% at one year and this 
decrease was sustained at three years. 
Methods
Treatment for problem opiate use in Ireland is provided by statutory and non-statutory services, including 
residential centres, community-based addiction services, general practices and prison services. 
For the purpose of the NDTRS, treatment is broadly defined as any activity which aims to ameliorate the 
psychological, medical or social state of individuals who seek help for their substance misuse problems. 
Clients who attend needle-exchange services are not included in this reporting system. Opiate treatment 
options include one or more of the following: medication (detoxification, methadone reduction and 
substitution programmes), brief intervention, counselling, medication free therapy, psychotherapy, family 
therapy, complementary therapy, and/or life-skills training.
Compliance with the NDTRS requires that one form be completed for each new client coming for first 
treatment and for each previously treated client returning to treatment. The NDTRS collects data on 
episodes of treatment in a calendar year, rather than on the individual person treated. This means that 
individuals may appear in the figures more than once if they receive treatment at more than one centre, or 
at the same centre more than once per year. Staff at the ADRU of the HRB compile anonymous, aggregated 
data from the NDTRS, which are analysed and reported at national and EU levels.
The main elements of the reporting system in the context of this paper are defined as follows:
All cases treated – describes individuals who receive treatment for problem opiate use at each treatment 
centre in a calendar year, and includes: 
Previously treated cases –  – describes individuals who were treated previously for problem opiate or 
other drug use at any treatment centre and have returned to treatment for problem opiate use in 
the reporting year; 
New cases treated –  – describes individuals who have never been treated for problem opiate or other 
drug use; and
Status unknown –  – describes individuals whose status with respect to previous treatment for 
problem opiate or other drug use is not known.
In the case of the data for ‘previously treated cases’, there is a possibility that individuals appear more than 
once in the database: for example, where a person receives treatment at more than one centre or at the 
same centre more than once per year. 
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Analysis
The data presented in this paper provide a description of cases treated for problem opiate use in Ireland 
between 2002 and 2007. The analysis provides an outline of the following: numbers treated; types of 
opiate used; incidence and prevalence of treated cases by year and by place of residence; additional 
problem substances; opiate-using behaviours; socio-demographic characteristics; service provision; and 
initial treatment intervention(s) provided. 
Numbers treated for problem opiate use
Of the 11,538 cases in treatment for problem opiate use in 2007, 7,643 (66%) were continuous care cases, 
that is, cases continuing in methadone treatment from the preceding calendar year and carried forward 
on 1 January 2007. The number of continuous care cases increased by 36%, from 5,601 in 2002 to 7,643 
in 2007 (Table 2). The number of previously treated cases increased by 15%, from 2,252 in 2002 to 2,598 
in 2007. The numbers of continuous care cases and previously treated cases are an indicator of a chronic 
situation and the requirement for addiction services into the future. The number of new cases increased by 
42%, from 809 in 2002 to 1,151 in 2007. The numbers of new cases entering treatment are an indirect 
indicator of recent trends in problem substance use. The number of methadone places increased by 54%, 
from 4,963 in 2001 (Reynolds et al. 2008) to 7,643 in 2007. 
Table 2 Opiate cases in treatment, by treatment status (NDTRS 2002–2007)
2002 2003 2004 2005 2006 2007
n % n % n % n % n % n %
All cases 8804 9113 9542 10217 10755 11538
Continuous care cases 5601 (63.3) 5944 (65.2) 6433 (67.4) 6924 (67.8) 7269 (67.6) 7643 (66.2)
Cases entering treatment 3203 (36.4) 3169 (34.8) 3109 (32.6) 3293 (32.2) 3486 (32.4) 3895 (33.8)
Of whom:
Previously treated cases 2252 (25.6) 2280 (25.0) 2265 (23.7) 2395 (23.4) 2352 (21.9) 2598 (22.5)
New cases 809 (9.2) 808 (8.9) 737 (7.7) 803 (7.9) 996 (9.3) 1151 (10.0)
Treatment status unknown* 142 (1.6) 81 (0.9) 107 (1.1) 95 (0.9) 138 (1.3) 146 (1.3)
* Relevant data not recorded on the NDTRS form returned.
Numbers entering treatment for problem opiate use, and types of opiate used
The remainder of the tabular analysis in this paper is based on 20,155 cases who lived in one of the four 
HSE regions and entered treatment for problem opiate use between 2002 and 2007. This represents an 
average of 3,359 cases entering treatment each year. 
Table 3 presents the total number of opiate cases entering treatment in the years 2002–2007. The total 
number in each year includes cases reporting opiates as their main problem substance (shown separately in 
Table 5) and cases reporting opiates as an additional problem substance (shown separately in Table 6). 
Of the 20,155 opiate cases entering treatment in the six-year period, 18,918 reported opiates as their main 
problem substance (Table 5) and 4,470 reported opiates as an additional problem substance (Table 6). 
These figures represent a considerable overlap, as 3,233 cases reported one type of opiate as their main 
problem substance and another type of opiate as an additional problem substance. 
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Of the 20,155 opiate cases in the years 2002 to 2007, 19,105 (95%) used heroin, 3,519 (15%) used either 
prescribed (509) or street (3,010) methadone, and 898 (4%) used other opiates (which included categories 
such as ‘unspecified opiates’ and ‘analgesics containing an opiate compound’). 
Overall, the number of opiate cases specifying heroin use increased by 20% between 2002 and 2007. 
Following a steady decrease between 2002 and 2004, the number increased substantially in the years 
2005–2007 (Table 3). 
The number of cases reporting problem methadone use decreased by 17% overall, from 599 in 2002 to 
498 in 2007, despite a peak of 648 cases in 2005 (Table 3). The number of cases reporting other opiates 
(including unspecified opiates and analgesics containing an opiate compound) as a problem substance 
increased by 22%, from 147 in 2002 to 179 in 2007. 
In total, 3,519 cases entered treatment for problem methadone use between 2002 and 2007. Although 
the overall number of cases decreased by 17%, street methadone use decreased by 25%, while prescribed 
methadone use increased by 164% (Table 4). In 2007, the majority (87%) used street methadone, while 
the remaining 13% used prescribed methadone. The cases using prescribed methadone were entering a 
detoxification facility after a period on methadone substitution.
There was an increase of 16% in the number of cases who reported opiates (including heroin, methadone 
or other opiates) as their main problem substance, from 3,077 cases in 2002 to 3,575 cases in 2007 (Table 
5). The number of cases who reported an opiate as an additional problem substance increased by 6%, from 
713 in 2002 to 757 in 2007 (Table 6). 
The number of new cases who entered treatment and reported heroin as a problem substance increased 
by 36% between 2002 and 2007, compared to a 15% increase among previously treated cases. The 
number of new cases reporting methadone as a problem substance was relatively small and decreased by 
21% between 2002 and 2007, compared to a 17% decrease among previously treated cases. Although 
the proportion of new cases reporting problem use of another type of opiate was small, the number of such 
cases increased by 169%, from 32 in 2002 to 86 in 2007 (Table 3).
Table 3 Opiate cases entering treatment,* by treatment status (NDTRS 2002–2007)
2002 2003 2004 2005 2006 2007
n % n % n % n % n % n %
All cases 3203 3169 3109 3293 3486 3895 
Heroin 3066 (80.4) 3008 (80.4) 2951 (80.3) 3085 (79.7) 3314 (81.5) 3681 (84.5)
Methadone 599 (15.7) 581 (15.5) 580 (15.8) 648 (16.7) 613 (15.1) 498 (11.4)
Other opiates† 147 (3.9) 151 (4.0) 143 (3.9) 137 (3.5) 141 (3.5) 179 (4.1)
Previously treated cases 2252 2280 2265 2395 2352 2598
Heroin 2154 (79.6) 2161 (80.7) 2169 (79.5) 2271 (79.9) 2263 (82.3) 2485 (84.4)
Methadone 446 (16.5) 411 (15.3) 475 (17.4) 497 (17.5) 414 (15.0) 371 (12.6)
Other opiates 106 (3.9) 107 (4.0) 86 (3.2) 73 (2.6) 74 (2.7) 88 (3.0)
New cases 809 808 737 803 996 1151
Heroin 778 (81.8) 773 (80.8) 685 (83.4) 724 (79.0) 923 (81.0) 1058 (84.2)
Methadone 141 (14.8) 145 (15.2) 87 (10.6) 132 (14.4) 154 (13.5) 112 (8.9)
Other opiates 32 (3.4) 39 (4.1) 49 (6.0) 60 (6.6) 63 (5.5) 86 (6.8)
Treatment status unknown 142 81 107 95 138 146
* Excludes cases not normally resident in Ireland.
† Other opiates include unspecified opiates and analgesics containing an opiate compound.
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Table 4 Opiate cases entering treatment* who reported methadone as a problem substance 
(NDTRS 2002–2007)
2002 2003 2004 2005 2006 2007
n % n % n % n % n % n %
All cases 599 581 580 648 613 498 
Street methadone 574 (95.8) 581 (100.0) 462 (79.7) 442 (68.2) 519 (84.7) 432 (86.7)
Prescribed methadone 25 (4.2) 0 (0.0) 118 (20.3) 206 (31.8) 94 (15.3) 66 (13.3)
* Excludes cases not normally resident in Ireland.
Table 5 Cases entering treatment* who reported opiates as their main problem substance, 
by treatment status (NDTRS 2002–2007)
2002 2003 2004 2005 2006 2007
n % n % n % n % n % n %
All cases 3077 3029 2863 3094 3280 3575
Heroin 2883 (93.7) 2828 (93.4) 2638 (92.1) 2851 (92.1) 3093 (94.3) 3364 (94.1)
Methadone 124 (4.0) 123 (4.1) 161 (5.6) 161 (5.2) 108 (3.3) 102 (2.9)
Other opiates 70 (2.3) 78 (2.6) 64 (2.2) 82 (2.7) 79 (2.4) 109 (3.0)
Previously treated cases 2181 2190 2108 2281 2237 2404
Heroin 2025 (92.8) 2035 (92.9) 1933 (91.7) 2111 (92.5) 2131 (95.3) 2280 (94.8)
Methadone 108 (5.0) 102 (4.7) 143 (6.8) 128 (5.6) 67 (3.0) 78 (3.2)
Other opiates 48 (2.2) 53 (2.4) 32 (1.5) 42 (1.8) 39 (1.7) 46 (1.9)
New cases 761 759 654 722 912 1032
Heroin 732 (96.2) 720 (94.9) 614 (93.9) 657 (91.0) 843 (92.4) 952 (92.2)
Methadone 14 (1.8) 18 (2.4) 14 (2.1) 28 (3.9) 32 (3.5) 19 (1.8)
Other opiates 15 (2.0) 21 (2.8) 26 (4.0) 37 (5.1) 37 (4.1) 61 (5.9)
* Excludes cases not normally resident in Ireland.
Table 6 Cases entering treatment* who reported opiates as an additional problem substance, 
by treatment status (NDTRS 2002–2007)
2002 2003 2004 2005 2006 2007
n % n % n % n % n % n %
All cases 713 685 789 755 771 757
Heroin 183 (25.7) 180 (26.3) 313 (39.7) 234 (31.0) 221 (28.7) 317 (41.9)
Methadone 475 (66.6) 458 (66.9) 419 (53.1) 487 (64.5) 505 (65.5) 396 (52.3)
Other opiates 77 (10.8) 73 (10.7) 79 (10.0) 55 (7.3) 62 (8.0) 70 (9.2)
Previously treated cases 506 472 550 503 456 451
Heroin 129 (24.6) 126 (25.8) 200 (35.1) 125 (24.3) 93 (20.1) 143 (30.8)
Methadone 338 (64.4) 309 (63.2) 330 (58.0) 364 (70.7) 344 (74.3) 290 (62.5)
Other opiates 58 (11.0) 54 (11.0) 39 (6.9) 26 (5.0) 26 (5.6) 31 (6.7)
New cases 187 190 121 146 188 164
Heroin 46 (24.2) 53 (26.8) 37 (30.1) 36 (24.0) 57 (29.4) 67 (39.0)
Methadone 127 (66.8) 127 (64.1) 73 (59.3) 98 (65.3) 120 (61.9) 86 (50.0)
Other opiates 17 (8.9) 18 (9.1) 13 (10.6) 16 (10.7) 17 (8.8) 19 (11.0)
* Excludes cases not normally resident in Ireland.
Incidence and prevalence of treated opiate use by year
Annual rates for the incidence (new cases) and prevalence (all cases) of treated opiate use between 2002 
and 2007 are expressed per 100,000 of the population aged 15–64 years, based on the census figures for 
2002 and 2006 and CSO estimated figures for 2007 (CSO 2007, 2008). 
12 HRB Trends Series 7
Figure 1 presents the annual incidence and prevalence of cases treated for opiates as their main problem 
substance. The incidence increased by 22%, with the numbers fluctuating from 28 in 2002, to 24 in 2004 
and to 35 in 2007. The prevalence data include all cases entering treatment each year and all cases carried 
over from the previous year. The prevalence increased by 15%, from 326 in 2002 to 376 in 2007.
Figure 1 Incidence and prevalence of cases treated for opiates as their main problem substance, 
per 100,000 of the 15–64-year-old population (NDTRS 2002–2007; CSO 2007, 2008)
Figure 2 presents the annual incidence of Dublin-resident and non-Dublin-resident cases treated for opiates 
as their main problem substance. While the incidence of Dublin cases decreased by 19% between 2002 
and 2007, that of non-Dublin cases increased by 126%. 
Figure 2 Incidence of cases treated for opiates as their main problem substance, per 100,000 of 
the 15–64-year-old population in Dublin and outside Dublin (NDTRS 2002–2007; CSO 
2007, 2008)
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Incidence and prevalence of treated opiate use by place of residence 
Almost half (49%) of all cases entering treatment in 2007 who reported opiates as their main problem 
substance lived in the HSE Dublin Mid-Leinster Region, while 30% lived in the HSE Dublin North East 
Region (Table 7). One-tenth of cases lived in the HSE South and HSE West regions. 
In 2007, 34% of new cases treated for opiates as their main problem substance lived in the HSE Dublin 
Mid-Leinster Region and a further 34% lived in the HSE Dublin North East Region. The lowest proportion 
(14%) lived in the HSE West Region (Table 7). 
Table 7 Cases entering treatment* who reported opiates as their main problem substance, 
by HSE region of residence and by treatment status (NDTRS 2002–2007)
2002 2003 2004 2005 2006 2007
HSE region of residence n % n % n % n % n % n %
All cases 3077 3029 2863 3094 3280 3575
Dublin North East 1005 (32.7) 1158 (38.2) 982 (34.3) 1154 (37.3) 1106 (33.7) 1084 (30.3)
Dublin Mid-Leinster 1820 (59.1) 1561 (51.5) 1620 (56.6) 1575 (50.9) 1639 (50.0) 1736 (48.6)
South 137 (4.5) 174 (5.7) 162 (5.7) 233 (7.5) 309 (9.4) 382 (10.7)
West 115 (3.7) 136 (4.5) 99 (3.5) 132 (4.3) 226 (6.9) 373 (10.4)
Previously treated cases 2181 2190 2108 2281 2237 2404
Dublin North East 701 (32.1) 845 (38.6) 745 (35.3) 850 (37.3) 716 (32.0) 679 (28.2)
Dublin Mid-Leinster 1338 (61.3) 1150 (52.5) 1206 (57.2) 1228 (53.8) 1234 (55.2) 1321 (55.0)
South 80 (3.7) 110 (5.0) 102 (4.8) 121 (5.3) 164 (7.3) 191 (7.9)
West 62 (2.8) 85 (3.9) 55 (2.6) 82 (3.6) 123 (5.5) 213 (8.9)
New cases 761 759 654 722 912 1032
Dublin North East 262 (34.4) 284 (37.4) 197 (30.1) 267 (37.0) 336 (36.8) 355 (34.4)
Dublin Mid-Leinster 403 (53.0) 368 (48.5) 361 (55.2) 300 (41.6) 337 (37.0) 350 (33.9)
South 53 (7.0) 64 (8.4) 57 (8.7) 109 (15.1) 140 (15.4) 180 (17.4)
West 43 (5.7) 43 (5.7) 39 (6.0) 46 (6.4) 99 (10.9) 147 (14.2)
Treatment status unknown 42 29 40 37 54 50
* Excludes cases not normally resident in Ireland.
Table 8 presents the number of new cases entering treatment in the period 2002–2007 who reported 
opiates as their main problem substance, by regional drugs task force (RDTF) area of residence. The South 
West and North Dublin RDTF areas reported the highest numbers; the North West RDTF area reported the 
lowest numbers. 
Table 8 New cases entering treatment* who reported opiates as their main problem substance, 
by regional drugs task force (RDTF) area of residence (NDTRS 2002–2007)
RDTF area of residence Number %
All new cases 4840 100.0
South West (of Dublin and Wicklow and all of 
Kildare) 1314 27.1
North Dublin City and County 1301 26.9
North Eastern 400 8.3
East Coast (of Dublin and Wicklow) 398 8.2
South Eastern 387 8.0
Midland 335 6.9
Southern 231 4.8
Mid-Western 229 4.7
Western 145 3.0
North West 43 0.9
Address in Ireland unknown 57 1.2
* Excludes cases not normally resident in Ireland.
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In 1996, NDTRS data were used to identify a number of local areas with problematic heroin use (Ministerial 
Task Force 1996). These areas were later designated as local drugs task force (LDTF) areas. The number of 
new opiate cases entering treatment for problem opiate use was highest in the North Inner City LDTF area, 
followed by the Clondalkin and Dublin North East LDTF areas (Table 9). Lower numbers of cases lived in the 
Canal Communities and Bray LDTF areas. The lower than expected number of new opiate cases in the Bray 
LDTF area may have been influenced by treatment availability in the area and low levels of participation in 
the NDTRS by service providers prior to 2007.
Table 9 New cases entering treatment* who reported opiates as their main problem substance, 
by local drugs task force (LDTF) area of residence (NDTRS 2002–2007)
LDTF, or other, area of residence Number %
All new cases 4840 100.0
North Inner City 346 7.1
Clondalkin 284 5.9
Dublin North East 270 5.6
Tallaght 261 5.4
Dun Laoghaire–Rathdown 241 5.0
South Inner City 239 4.9
Finglas–Cabra 181 3.7
Ballymun 158 3.3
Blanchardstown 127 2.6
Ballyfermot 126 2.6
Dublin 12 101 2.1
Canal Communities 85 1.8
Bray 62 1.3
Rest of Dublin 706 14.6
Outside Dublin (excluding Bray) 1653 34.2
* Excludes cases not normally resident in Ireland.
In order to adjust for variation in population size by geographical area, the incidence of treated opiate use 
in each area was calculated using the annual average number of new cases for the six-year period living 
in each of the 10 regional drugs task force areas, 26 counties and 32 local health office areas; this average 
was divided by the population aged 15–64 years living in the respective regional drugs task force areas and 
counties, using the census figures for 2002 and 2006 and CSO estimated figures for 2007, and for local 
health office areas using CSO estimated figures for 2007 only CSO (2007, 2008). 
Between 2002 and 2007, the average annual incidence of new cases treated for opiates as their main 
problem substance was highest in the North Dublin City and County RDTF area (at 60 cases per 100,000 
of the 15–64-year-old population), followed by the South West RDTF area (Kildare and parts of Dublin and 
Wicklow) (at 50 cases), and the Midland RDTF area (at 35 cases) (Figure 3). The North West RDTF area 
had the lowest incidence, at four cases per 100,000, indicating one or both of the following: lower rates 
of opiate use in this area than in the rest of Ireland, or lower access to or uptake of appropriate treatment 
services. The former is the most likely explanation.
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Figure 3 Average annual incidence of cases treated for opiates as their main problem substance, by 
regional drugs task force area of residence, per 100,000 of the 15–64-year-old population 
(NDTRS 2002–2007; CSO 2007, 2008)
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Data presented by county indicate that the highest numbers of new cases reporting opiates as their main 
problem substance between 2002 and 2007 lived in Dublin, and the lowest numbers lived in Leitrim, Sligo 
and Monaghan (Table 10). 
Table 10 New cases entering treatment* who reported opiates as their main problem substance, 
by county of residence (NDTRS 2002–2007)
County of residence Number %
All new cases 4840 100.0
Dublin 2767 57.2
Cork 206 4.3
Louth 188 3.9
Limerick 171 3.5
Kildare 163 3.4
Meath 157 3.2
Wicklow 140 2.9
Wexford 124 2.6
Laois 123 2.5
Westmeath 116 2.4
Carlow 109 2.3
Galway 102 2.1
Waterford 94 1.9
Offaly 67 1.4
Cavan 45 0.9
Clare 32 0.7
Kilkenny 31 0.6
Donegal 30 0.6
Longford 29 0.6
Roscommon 29 0.6
Tipperary (SR) 29 0.6
Tipperary (NR) 25 0.5
Kerry 23 0.5
Mayo 14 0.3
Monaghan 9 0.2
Sligo 9 0.2
Leitrim ~ 0.1
Address in Ireland unknown ~ 0.1
* Excludes cases not normally resident in Ireland.
~ Numbers of cases less than five cannot be reported.
The average annual incidence of new cases treated for opiates as their main problem substance was 
examined by county for the period 2002–2007 (Figure 4). The average incidence for the period was highest 
in Dublin and Carlow (with over 54 cases per 100,000 of the 15–64-year-old population) followed by Laois, 
Louth, Westmeath, and Wicklow (with between 28 and 48 cases). The incidence was lowest in counties 
located mainly in the west and north-west of the country (with between 3 and 5 cases per 100,000).
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Figure 4 Average annual incidence of cases treated for opiates as their main problem substance, by 
county of residence, per 100,000 of the 15–64-year-old population (NDTRS 2002–2007; 
CSO 2007, 2008)
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The highest numbers of new cases reporting opiates as their main problem substance between 2002 and 
2007 lived in Dublin West, Dublin North Central and Dublin North West local health office (LHO) areas; the 
lowest number lived in the Sligo/Leitrim LHO area (Table 11). 
Table 11 New cases entering treatment* who reported opiates as their main problem substance, 
by local health office (LHO) area of residence (NDTRS 2002–2007)
LHO area of residence Number %
All new cases 4840 100.0
Dublin West 491 10.1
Dublin North Central 478 9.9
North West Dublin 439 9.1
North Dublin 381 7.9
Dublin South West 375 7.7
Dublin South City 322 6.7
Cork 206 4.3
Laois/Offaly 190 3.9
Louth 188 3.9
Limerick 171 3.5
Kildare and South West Wicklow 167 3.5
Dublin South 164 3.4
Meath 157 3.2
Longford/Westmeath 145 3.0
Carlow/Kilkenny 140 2.9
Wexford 124 2.6
Dublin South East 117 2.4
Wicklow (East coast) 117 2.4
Galway 102 2.1
Waterford 94 1.9
Cavan/Monaghan 54 1.1
Clare 32 0.7
Donegal 30 0.6
Roscommon 29 0.6
Tipperary SR 29 0.6
Tipperary NR 25 0.5
Kerry 23 0.5
Mayo 14 0.3
Sligo/Leitrim 13 0.3
LHO area unknown 23 0.5
* Excludes cases not normally resident in Ireland.
The average annual incidence of new cases treated for opiates as their main problem substance was 
examined by LHO area of residence for the period 2002–2007 (Figure 5). The incidence was highest in 
Dublin North Central, Dublin West, Dublin South West, Dublin North West, and Dublin South City areas 
(with over 50 cases per 100,000 of the 15–64-year-old population), followed by Louth, Dublin North, Laois/
Offaly, Dublin South and Longford/ Westmeath areas (with over 30 cases). The incidence was lowest in the 
LHO areas located mainly in the west and north-west of the country (with between 3 and 5 cases).
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Figure 5 Average annual incidence of cases treated for opiates as their main problem substance, 
by local health office (LHO) area, per 100,000 of the 15–64-year-old population (NDTRS 
2002–2007; CSO 2007, 2008)
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Main problem substance where opiates were an additional problem substance
In 2007 the main problem substances associated with opiates as an additional problem substance were 
other opiates (56%) and, to a lesser extent, alcohol (16%) and cocaine (12%) (Table 12). 
Table 12 Main problem substance used by cases entering treatment* who reported opiates as an 
additional problem substance (NDTRS 2002–2007)
2002 2003 2004 2005 2006 2007
Cases reporting opiates 
as an additional problem 
substance 713 685 789 755 771 757
Main problem substance n % n % n % n % n % n %
Other opiates 587 (82.3) 545 (79.6) 543 (68.8) 556 (73.6) 565 (73.3) 437 (57.7)
Alcohol n.a.† n.a.† 98 (12.4) 85 (11.3) 84 (10.9) 124 (16.4)
Cocaine 24 (3.4) 57 (8.3) 67 (8.5) 62 (8.2) 62 (8.0) 91 (12.0)
Cannabis 67 (9.4) 52 (7.6) 32 (4.1) 31 (4.1) 36 (4.7) 44 (5.8)
Benzodiazepines 19 (2.7) 16 (2.3) 39 (4.9) 16 (2.1) 21 (2.7) 43 (5.7)
Ecstasy 7 (1.0) 8 (1.2) 5 (0.6) 4 (0.5) 2 (0.3) 6 (0.8)
Amphetamines 1 (0.1) 3 (0.4) 1 (0.1) 0 (0.0) 1 (0.1) 5 (0.7)
Volatile inhalants 0 (0.0) 1 (0.1) 0 (0.0) 0 (0.0) 0 (0.0) 4 (0.5)
Other 8 (1.1) 3 (0.4) 4 (0.5) 1 (0.1) 0 (0.0) 3 (0.4)
* Excludes cases not normally resident in Ireland.
† Not available: the NDTRS did not record alcohol as a main problem substance prior to 2004.
Additional problem substances where an opiate was the main problem substance
The proportion of cases treated for opiates as their main problem substance who reported use of more than 
one substance decreased from 69% in 2002 to 63% in 2007 (Table 13). The decrease in polysubstance use 
was observed among both new and previously treated opiate cases, but was more marked among the new 
cases. The reason for the decrease is not clear; it may be the result of an increase in the number of newer 
opiate users who have yet to develop chronic polysubstance-using practices, or improved history-taking by 
service providers. Polysubstance use is one of the factors that can impede successful treatment for problem 
opiate use. Specific interventions are required to address this problem.
Table 13 Polysubstance use by cases entering treatment* who reported opiates as their main 
problem substance, by treatment status (NDTRS 2002–2007)
2002 2003 2004 2005 2006 2007
n % n % n % n % n % n %
All cases 3077 3029 2863 3094 3280 3575
All cases who used more 
than one substance 2114 (68.7) 2139 (70.6) 1932 (67.5) 2120 (68.5) 2261 (68.9) 2239 (62.6)
Previously treated cases 2181 2190 2108 2281 2237 2404
Previously treated cases 
who used more than one 
substance 1500 (68.8) 1532 (70.0) 1449 (68.7) 1566 (68.7) 1559 (69.7) 1555 (64.7)
New cases 761 759 654 722 912 1032
New cases who used more 
than one substance 540 (71.0) 557 (73.4) 424 (64.8) 492 (68.1) 608 (66.7) 613 (59.4)
Treatment status unknown 42 29 40 37 54 50
* Excludes cases not normally resident in Ireland.
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Of the cases who entered treatment in 2007 and reported opiates as their main problem substance, 26% 
reported problem use of two substances, 21% of three substances and 16% of four or more substances 
(Table 14). During the period under review, when opiate cases reported use of an additional problem 
substance they most commonly reported one additional substance as part of their current problem 
substance use. The trends were similar for previously treated and new cases. 
Table 14 Number of problem substances used by cases entering treatment* who reported opiates 
as their main problem substance, by treatment status (NDTRS 2002–2007)
2002 2003 2004 2005 2006 2007
Number of problem 
substances used n % n % n % n % n % n %
All cases 3077 3029 2863 3094 3280 3575
One substance 963 (31.3) 890 (29.4) 931 (32.5) 974 (31.5) 1019 (31.1) 1336 (37.4)
Two substances 912 (29.6) 876 (28.9) 784 (27.4) 886 (28.6) 848 (25.9) 931 (26.0)
Three substances 678 (22.0) 716 (23.6) 713 (24.9) 695 (22.5) 736 (22.4) 753 (21.1)
Four substances 524 (17.0) 547 (18.1) 435 (15.2) 539 (17.4) 677 (20.6) 555 (15.5)
Previously treated cases 2181 2190 2108 2281 2237 2404
One substance 681 (31.2) 658 (30.0) 659 (31.3) 715 (31.3) 678 (30.3) 849 (35.3)
Two substances 630 (28.9) 643 (29.4) 574 (27.2) 647 (28.4) 570 (25.5) 647 (26.9)
Three substances 505 (23.2) 518 (23.7) 559 (26.5) 525 (23.0) 515 (23.0) 524 (21.8)
Four substances 365 (16.7) 371 (16.9) 316 (15.0) 394 (17.3) 474 (21.2) 384 (16.0)
New cases 761 759 654 722 912 1032
One substance 221 (29.0) 202 (26.6) 230 (35.2) 230 (31.9) 304 (33.3) 419 (40.6)
Two substances 242 (31.8) 219 (28.9) 184 (28.1) 216 (29.9) 248 (27.2) 249 (24.1)
Three substances 161 (21.2) 187 (24.6) 132 (20.2) 147 (20.4) 183 (20.1) 205 (19.9)
Four substances 137 (18.0) 151 (19.9) 108 (16.5) 129 (17.9) 177 (19.4) 159 (15.4)
Treatment status unknown 42 29 40 37 54 50
* Excludes cases not normally resident in Ireland.
Table 15 shows the additional problem substances used by cases entering treatment who reported 
opiates as their main problem substance. Cannabis, benzodiazepines and cocaine were the most common 
additional problem substances reported between 2002 and 2007. Cannabis was top of this list in each 
of the six years. Benzodiazepines was the second most common additional substance between 2002 and 
2005, but was replaced by cocaine in 2006 and 2007. The number reporting cocaine as an additional 
problem substance increased by 59% over the period. The number reporting alcohol as an additional 
problem substance increased by 250%. These trends were similar among previously treated and new 
opiate cases. 
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Table 15 Additional problem substances used by cases entering treatment* who reported opiates as 
their main problem substance, by treatment status (NDTRS 2002–2007)
2002 2003 2004 2005 2006 2007
Additional problem 
substances used† n % n % n % n % n % n %
All cases 2114 2138 1932 2120 2261 2239
Cannabis 1075 (50.9) 1115 (52.2) 934 (48.3) 1060 (50.0) 1194 (52.8) 1106 (49.4)
Benzodiazepines 1005 (47.5) 909 (42.5) 785 (40.6) 875 (41.3) 936 (41.4) 788 (35.2)
Cocaine 609 (28.8) 782 (36.6) 752 (38.9) 811 (38.3) 966 (42.7) 969 (43.3)
Opiates‡ 598 (28.3) 559 (26.1) 550 (28.5) 560 (26.4) 572 (25.3) 443 (19.8)
Alcohol 153 (7.2) 246 (11.5) 245 (12.7) 332 (15.7) 457 (20.2) 536 (23.9)
Ecstasy 255 (12.1) 225 (10.5) 152 (7.9) 169 (8.0) 134 (5.9) 140 (6.3)
Amphetamines 59 (2.8) 47 (2.2) 31 (1.6) 23 (1.1) 40 (1.8) 45 (2.0)
Volatile inhalants 10 (0.5) 6 (0.3) 7 (0.4) 6 (0.3) 4 (0.2) 6 (0.3)
Other substances 57 (2.7) 48 (2.2) 49 (2.5) 45 (2.1) 37 (1.6) 50 (2.2)
Previously treated cases 1500 1531 1449 1566 1559 1555
Cannabis 722 (48.1) 733 (47.9) 670 (46.2) 748 (47.8) 794 (50.9) 727 (46.8)
Cocaine 424 (28.3) 549 (35.9) 556 (38.4) 625 (39.9) 708 (45.4) 697 (44.8)
Benzodiazepines 782 (52.1) 726 (47.4) 630 (43.5) 698 (44.6) 716 (45.9) 596 (38.3)
Opiates‡ 445 (29.7) 391 (25.5) 451 (31.1) 435 (27.8) 394 (25.3) 334 (21.5)
Alcohol 112 (7.5) 185 (12.1) 169 (11.7) 216 (13.8) 279 (17.9) 324 (20.8)
Ecstasy 157 (10.5) 134 (8.8) 98 (6.8) 103 (6.6) 78 (5.0) 88 (5.7)
Amphetamines 39 (2.6) 27 (1.8) 16 (1.1) 14 (0.9) 24 (1.5) 28 (1.8)
Volatile inhalants 5 (0.3) 4 (0.3) 6 (0.4) 2 (0.1) 3 (0.2) 3 (0.2)
Other substances 36 (2.4) 34 (2.2) 36 (2.5) 30 (1.9) 20 (1.3) 35 (2.3)
New cases 540 557 424 492 608 613
Cannabis 314 (58.1) 343 (61.6) 244 (57.5) 277 (56.3) 340 (55.9) 342 (55.8)
Cocaine 156 (28.9) 211 (37.9) 175 (41.3) 167 (33.9) 205 (33.7) 247 (40.3)
Benzodiazepines 195 (36.1) 160 (28.7) 127 (30.0) 152 (30.9) 201 (33.1) 177 (28.9)
Opiates‡ 140 (25.9) 145 (26.0) 83 (19.6) 107 (21.7) 140 (23.0) 97 (15.8)
Alcohol 37 (6.9) 58 (10.4) 67 (15.8) 106 (21.5) 167 (27.5) 186 (30.3)
Ecstasy 88 (16.3) 90 (16.2) 50 (11.8) 60 (12.2) 56 (9.2) 49 (8.0)
Amphetamines 18 (3.3) 20 (3.6) 15 (3.5) 9 (1.8) 14 (2.3) 17 (2.8)
Volatile inhalants 4 (0.7) 2 (0.4) 1 (0.2) 2 (0.4) 1 (0.2) 2 (0.3)
Other substances 18 (3.3) 14 (2.5) 8 (1.9) 13 (2.6) 16 (2.6) 15 (2.4)
Treatment status unknown 74 50 59 62 94 71
* Excludes cases not normally resident in Ireland.
† By cases reporting use of one, two or three additional substances
‡ Cases may report one type of opiate as their main problem substance and another type of opiate as an additional problem substance.
Opiate-using behaviours
Of the 3,575 cases who entered treatment and reported opiates as their main problem substance in 2007, 
52% smoked it, 40% injected it, and 5% consumed it orally (Table 16). From 2003 to 2007, decreasing 
proportions of cases reported injecting as their primary route of administration, while correspondingly 
increasing proportions reported smoking as their primary route. Similar trends were noted among new and 
previously treated opiate cases. Overall, the proportion of injectors was higher among previously treated 
cases than among new cases, although it decreased by 13% between 2002 and 2007, which may be partly 
explained by the fact that older opiate users with seriously damaged veins revert to smoking opiates. 
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Table 16 Route of administration for cases entering treatment* who reported opiates as their main 
problem substance, by treatment status (NDTRS 2002–2007)
2002 2003 2004 2005 2006 2007
n % n % n % n % n % n %
All cases 3077 3029 2863 3094 3280 3575
Inject 1647 (53.5) 1650 (54.5) 1345 (47.0) 1410 (45.6) 1350 (41.2) 1424 (39.8)
Smoke 1172 (38.1) 1139 (37.6) 1185 (41.4) 1359 (43.9) 1681 (51.3) 1847 (51.7)
Eat or drink 151 (4.9) 166 (5.5) 199 (7.0) 219 (7.1) 175 (5.3) 184 (5.1)
Sniff or snort 16 (0.5) 1 (0.0) 3 (0.1) 0 (0.0) 0 (0.0) 0 (0.0)
Other 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.0)
Not recorded 91 (3.0) 73 (2.4) 131 (4.6) 106 (3.4) 74 (2.3) 119 (3.3)
Previously treated cases 2181 2190 2108 2281 2237 2404
Inject 1299 (59.6) 1272 (58.1) 1071 (50.8) 1150 (50.4) 1072 (47.9) 1121 (46.6)
Smoke 681 (31.2) 731 (33.4) 777 (36.9) 891 (39.1) 1013 (45.3) 1107 (46.0)
Eat or drink 126 (5.8) 125 (5.7) 160 (7.6) 152 (6.7) 95 (4.2) 116 (4.8)
Sniff or snort 9 (0.4) 0 (0.0) 2 (0.1) 0 (0.0) 0 (0.0) 0 (0.0)
Not recorded 66 (3.0) 62 (2.8) 98 (4.6) 88 (3.9) 57 (2.5) 60 (2.5)
New cases 761 759 654 722 912 1032
Inject 292 (38.4) 342 (45.1) 225 (34.4) 222 (30.7) 233 (25.5) 266 (25.8)
Smoke 433 (56.9) 377 (49.7) 377 (57.6) 429 (59.4) 600 (65.8) 674 (65.3)
Eat or drink 23 (3.0) 37 (4.9) 36 (5.5) 60 (8.3) 69 (7.6) 63 (6.1)
Sniff or snort 7 (0.9) 1 (0.1) 1 (0.2) 0 (0.0) 0 (0.0) 0 (0.0)
Other 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.1)
Not recorded 6 (0.8) 2 (0.3) 15 (2.3) 11 (1.5) 10 (1.1) 28 (2.7)
Treatment status unknown 42 29 40 37 54 50
* Excludes cases not normally resident in Ireland.
From 2002 to 2007, decreasing proportions of cases living in Dublin reported injecting as their primary 
route of administration, while correspondingly increasing proportions reported smoking opiates (Figure 6). 
Overall, the number of cases who reported injecting decreased by 26%, while smoking increased by 24%. 
In 2007 just over one-quarter of new opiate cases living in Dublin injected the drug.
The majority of new opiate cases living outside Dublin smoked the drug (Figure 7). The proportion of 
injectors decreased between 2002 and 2007. During the initial years of the emerging opiate epidemic 
outside Dublin, the limited treatment services prioritised the more serious cases, that is, those injecting 
opiates. As services expanded during the acute phase of the epidemic, treatment places became available 
for a larger number of opiate users and the newer users were attracted into treatment at an earlier stage in 
their opiate-using career, while still smoking their opiate of choice.
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Figure 6 Route of administration for new cases living in Dublin who reported opiates as their main 
problem substance (NDTRS 2002–2007)
Figure 7 Route of administration for new cases living outside Dublin who reported opiates as their 
main problem substance (NDTRS 2002–2007)
Of the 3,575 cases who entered treatment in 2007 and reported opiates as their main problem substance, 
54% used it daily, 10% used it on two to six days per week, 6% used it once per week or less and 25% had 
not used it in the month prior to entering treatment (Table 17). The proportion of daily users was much 
higher among new cases (70%) than among previously treated cases (48%). There was a 26% increase in 
the proportion of cases reporting daily use of opiates during the reporting period; the number of new cases 
reporting daily use increased by 36%. 
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Table 17 Frequency of opiate use in the month prior to entering treatment by cases* who reported 
opiates as their main problem substance, by treatment status (NDTRS 2002–2007)
2002 2003 2004 2005 2006 2007
n % n % n % n % n % n %
All cases 3077 3029 2863 3094 3280 3575
Daily 1533 (49.8) 1511 (49.9) 1520 (53.1) 1585 (51.2) 1776 (54.1) 1939 (54.2)
2–6 days per week 246 (8.0) 291 (9.6) 225 (7.9) 248 (8.0) 329 (10.0) 349 (9.8)
Once a week or less 225 (7.3) 219 (7.2) 145 (5.1) 197 (6.4) 245 (7.5) 223 (6.2)
No use in the last month 818 (26.6) 826 (27.3) 698 (24.4) 864 (27.9) 781 (23.8) 899 (25.1)
Not known 255 (8.3) 182 (6.0) 275 (9.6) 200 (6.5) 149 (4.5) 165 (4.6)
Previously treated cases 2181 2190 2108 2281 2237 2404
Daily 939 (43.1) 944 (43.1) 1002 (47.5) 1036 (45.4) 1108 (49.5) 1145 (47.6)
2–6 days per week 163 (7.5) 210 (9.6) 153 (7.3) 163 (7.1) 211 (9.4) 236 (9.8)
Once a week or less 172 (7.9) 173 (7.9) 126 (6.0) 164 (7.2) 173 (7.7) 183 (7.6)
No use in the last month 726 (33.3) 717 (32.7) 609 (28.9) 749 (32.8) 648 (29.0) 740 (30.8)
Not known 181 (8.3) 146 (6.7) 218 (10.3) 169 (7.4) 97 (4.3) 100 (4.2)
New cases 761 759 654 722 912 1032
Daily 533 (70.0) 535 (70.5) 474 (72.5) 507 (70.2) 609 (66.8) 724 (70.2)
2–6 days per week 71 (9.3) 71 (9.4) 63 (9.6) 75 (10.4) 99 (10.9) 102 (9.9)
Once a week or less 48 (6.3) 43 (5.7) 17 (2.6) 31 (4.3) 57 (6.3) 35 (3.4)
No use in the last month 75 (9.9) 86 (11.3) 68 (10.4) 92 (12.7) 108 (11.8) 143 (13.9)
Not known 34 (4.5) 24 (3.2) 32 (4.9) 17 (2.4) 39 (4.3) 28 (2.7)
Treatment status unknown 42 29 40 37 54 50
* Excludes cases not normally resident in Ireland.
Between 2002 and 2007, the median age at which new opiate cases commenced illicit use of drugs was 
15 years (Table 18). The median age at which new cases commenced opiate use was 19 years. Half of the 
new opiate cases had used opiates for five years or more before seeking treatment. These findings indicate 
that opiate cases tended to use other drugs prior to commencing opiate use and that they used one or 
more opiates for a considerable period before seeking treatment. The median age at which new cases 
commenced injecting was 20 years. In the interval between commencing opiate use and seeking treatment, 
a significant minority of opiate users change from smoking to injecting opiates, and may subsequently 
contract blood-borne viruses, such as hepatitis C, indicating the need for proactive interventions to bring 
opiate users into treatment earlier.
Table 18 Median age (range†) at significant points, and time in years between first use of opiates 
and first seeking treatment, for new cases who reported opiates as their main problem 
substance (NDTRS 2002–2007)
New cases (n=4840)
Age first used any 
drug (n=4335)
Age first used 
opiates (n=4440)
Age first injected 
(n=2080)
Age first sought 
treatment 
(n=4831)
Years between 
first use of 
opiates and first 
seeking treatment 
(n=4440)
Median age/time 
(range†) in years 15 (11–25) 19 (14–33) 20 (15–32) 26 (18–41) 5 (1–7)
* Excludes cases not normally resident in Ireland.
† Age range presented is 5th percentile to 95th percentile (90% of cases are included within this range).
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Socio-demographic characteristics
The median age of previously treated cases entering treatment for opiates as their main problem substance 
increased from 26 to 29 years between 2002 and 2007, while the median age of new cases increased from 
24 to 27 years (Table 19). In 2007, almost 3% of new cases were under 18 years of age, while less than 
1% of previously treated cases were in this age group. The proportion of new cases aged under 18 years 
increased between 2006 and 2007, which possibly reflects the increase in adolescent treatment services 
and their compliance with the NDTRS. In 2007, 73% of cases entering treatment for opiates as their main 
problem substance were male; only 13% were employed, a considerable decrease when compared to 
the figure of 21% in 2002. In 2007, the proportion of opiate cases who reported leaving school early was 
higher among previously treated cases (26%) than among new cases (21%). During the period under 
review, very few opiate cases aged under 18 reported that they were still at school. One in twenty of the 
opiate cases entering treatment each year reported being homeless.
Table 19 Socio–economic characteristics of cases entering treatment* who reported opiates as their 
main problem substance, by treatment status (NDTRS 2002–2007)
2002 2003 2004 2005 2006 2007
Characteristics of cases† n % n % n % n % n % n %
All cases 3077 3029 2863 3094 3280 3575
Median age (range‡) 26 (19 – 40) 26 (19 – 41) 27 (20 – 41) 28 (20 – 42) 28 (20 – 43) 29 (20 – 43)
Under 18 years 61 (2.0) 24 (0.8) 23 (0.8) 28 (0.9) 38 (1.2) 40 (1.1)
Male 2099 (68.2) 2056 (67.9) 1985 (69.3) 2149 (69.5) 2391 (72.9) 2609 (73.0)
Living with parents/family 1649 (53.6) 1529 (50.5) 1341 (46.8) 1400 (45.2) 1547 (47.2) 1583 (44.3)
Homeless 91 (3.0) 146 (4.8) 153 (5.3) 171 (5.5) 182 (5.5) 196 (5.5)
Non-Irish nationals 81 (2.6) 99 (3.3) 72 (2.5) 103 (3.3) 142 (4.3) 170 (4.8)
Early school leavers 686 (22.3) 712 (23.5) 666 (23.3) 754 (24.4) 779 (23.8) 875 (24.5)
Still at school 8 (0.3) 12 (0.4) ~ 6 (0.2) 10 (0.3) 12 (0.3)
Employed (aged 16–64) 636 (20.9) 550 (18.2) 503 (17.6) 517 (16.7) 549 (16.8) 475 (13.3)
Previously treated cases 2181 2190 2108 2281 2237 2404
Median age (range‡) 26 (19 – 40) 27 (20 – 41) 27 (20 – 40) 29 (21 – 42) 29 (21 – 43) 29 (21 – 43)
Under 18 years 27 (1.2) 8 (0.4) 7 (0.3) 11 (0.5) 17 (0.8) 11 (0.5)
Male 1483 (68.0) 1487 (67.9) 1455 (69.0) 1581 (69.3) 1630 (72.9) 1758 (73.1)
Living with parents/family 1152 (52.8) 1111 (50.7) 994 (47.2) 1036 (45.4) 1058 (47.3) 1044 (43.4)
Homeless 61 (2.8) 101 (4.6) 119 (5.6) 133 (5.8) 124 (5.5) 145 (6.0)
Non-Irish nationals 51 (2.3) 64 (2.9) 55 (2.6) 54 (2.4) 77 (3.4) 114 (4.7)
Early school leavers 502 (23.0) 514 (23.5) 514 (24.4) 584 (25.6) 564 (25.2) 633 (26.3)
Still at school ~ ~ ~ ~ ~ ~
Employed (aged 16–64) 443 (20.5) 397 (18.2) 337 (16.0) 351 (15.4) 333 (14.9) 271 (11.3)
New cases 761 759 654 722 912 1032
Median age (range‡) 24 (18 – 38) 25 (18 - 41) 25 (18 - 40) 27 (19 – 41) 27 (19 – 42) 27 (18 – 44)
Under 18 years 32 (4.2) 16 (2.1) 16 (2.4) 17 (2.4) 18 (2.0) 27 (2.6)
Male 520 (68.3) 515 (67.9) 460 (70.3) 504 (69.8) 673 (73.8) 736 (71.3)
Living with parents/family 442 (58.1) 394 (51.9) 305 (46.6) 323 (44.7) 425 (46.6) 470 (45.5)
Homeless 26 (3.4) 39 (5.1) 26 (4.0) 32 (4.4) 54 (5.9) 42 (4.1)
Non-Irish nationals 21 (2.8) 33 (4.3) 14 (2.1) 47 (6.5) 58 (6.4) 51 (4.9)
Early school leavers 165 (21.7) 185 (24.4) 134 (20.5) 149 (20.6) 182 (20.0) 219 (21.2)
Still at school ~ 9 (1.2) ~ ~ 7 (0.8) 8 (0.8)
Employed (aged 16–64) 168 (22.4) 140 (18.5) 150 (23.0) 154 (21.4) 197 (21.7) 178 (17.3)
Treatment status unknown 42 29 40 37 54 50
* Excludes cases not normally resident in Ireland.
† It is not possible to ascertain the percentage with each characteristic of interest from the total number because not all forms had 
complete data. 
‡ Age range presented is 5th percentile to 95th percentile (90% of cases are included within this range).
~ Numbers of cases less than five cannot be reported. 
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Service provision
The total number of cases entering treatment and reporting opiates as a problem substance increased by 
22%, from 3,203 in 2002 to 3,895 in 2007 (Table 20). In 2007 the majority (75%) of cases attended an 
outpatient service for treatment. The largest increase was in entries to inpatient services, where the number 
of cases reporting opiates as a problem substance increased by 105%, from 308 in 2002 to 631 in 2007. 
The number of cases entering treatment in general practice settings decreased by 34% between 2002 and 
2007, which indicates that the present number of general practitioner places is inadequate, and that there 
is a need to expand the number of primary care practitioners involved in methadone treatment. A small 
proportion of opiate cases entered treatment in low-threshold settings, with the number decreasing by 
45% between 2002 and 2007. 
Table 20 Cases entering treatment* who reported opiates as a problem substance, by type of 
service provider (NDTRS 2002–2007) 
2002 2003 2004 2005 2006 2007
All cases 3203 3169 3109 3293 3486 3895 
Outpatient 2377 (74.2) 2203 (69.5) 2101 (67.6) 2380 (72.3) 2650 (76.0) 2937 (75.4)
Inpatient 308 (9.6) 417 (13.2) 432 (13.9) 438 (13.3) 481 (13.8) 631 (16.2)
Low-threshold† 101 (3.2) 150 (4.7) 183 (5.9) 143 (4.3) 116 (3.3) 56 (1.4)
General practitioner 411 (12.8) 391 (12.3) 393 (12.6) 332 (10.1) 239 (6.9) 271 (7.0)
Service type unknown‡ 6 (0.2) 8 (0.3) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
* Excludes cases not normally resident in Ireland.
† Low-threshold services are services that provide low-dose methadone or drop-in facilities only.
‡ Relevant data not recorded on the NDTRS forms returned.
Treatment provision
It is recognised that, given the complex nature of problems associated with opiate misuse, there is no single 
treatment modality for problem opiate use. A broad range of services covering treatment and rehabilitation 
is provided throughout the country. Of the 3,575 cases entering treatment in 2007 who reported opiates as 
their main problem substance, 53% received counselling, 46% commenced methadone maintenance, 23% 
received a brief intervention, and 10% commenced a medically assisted opiate detoxification (Figure 8). 
Over 46% of cases received more than one initial treatment intervention (Figure 9). It is important to note 
that the NDTRS form records only the initial treatment provided in each case. Treatment interventions that 
may be provided subsequently are not recorded. In recent years there has been an increase in the types 
of intervention provided and a greater emphasis on brief intervention, counselling (including cognitive 
behaviour therapy), family therapy, aftercare and social re-integration. 
In 2007 the NDTRS introduced a form to measure immediate outcomes. The form records all treatment 
interventions received by a client during a treatment episode, along with details of their treatment outcome 
at the time of discharge or transfer to another service. 
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Figure 8 Percentage of cases entering treatment who reported opiates as their main problem 
substance, by type of initial treatment intervention availed of (NDTRS 2007)
Figure 9 Percentage of cases entering treatment who reported opiates as their main problem 
substance, by the number of treatment interventions availed of (NDTRS 2007)
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Conclusions
Alcohol, followed by opiates and cocaine, three substances with high harm indicators, are the most 
common substances of dependence in Ireland. The analysis presented in this paper was undertaken to 
inform policy making and service planning in relation to opiate treatment. Three out of every five people 
entering treatment use an opiate as their main problem substance. The increase in the number of new 
opiate cases is an indicator of an increase in problem opiate use among the general population; this is 
particularly evident in counties outside Dublin. The increase in the total number of opiate cases treated 
is an indicator of an increase in service provision for opiate users and an increase in compliance with the 
reporting system. 
The data presented in this paper show significant increases in the number of opiate cases presenting to 
drug treatment services between 2002 and 2007. While problem opiate use is predominantly a Dublin 
issue, every county in Ireland was represented in the treatment data for the reporting period. 
A total of 11,392 cases were treated for problem opiate (mainly heroin) use in 2007. The number of cases 
who reported an opiate as a problem substance increased by 29%, from 8,804 in 2002 to 11,392 in 2007. 
The increase in cases receiving opiate treatment was in line with increases in heroin seizures in 2005 and 
2006, and in heroin-related deaths in 2004 and 2005. The larger increases in new opiate cases occurred 
mainly outside Dublin, particularly in the north eastern, midland and south eastern counties. New opiate 
cases generally used other drugs before they started using opiates, and they used opiates for a considerable 
period before seeking treatment. The vast majority of new cases treated between 2002 and 2007 reported 
problem use of more than one substance (polysubstance use), which is a major challenge facing drug 
services. 
From 2003 to 2007, decreasing proportions of cases reported injecting as their primary route of 
administration, while correspondingly increasing proportions reported smoking opiates. This indicates that 
the transmission of blood-borne viruses will be reduced among this cohort. The majority of cases who 
reported an opiate as their main problem substance used it daily, indicating the addictive nature of the 
drug. 
In general, problem opiate users are young and male, have low levels of education and are unlikely 
to be employed. This profile highlights the importance of personal development and educational 
and employment opportunities as part of the drug treatment and reintegration process. A variety of 
effective interventions is provided to opiate cases. Findings from the ROSIE study indicate that the main 
achievements of clients in the first year of opiate treatment were reductions in drug use and in drug-related 
crime, while the most significant achievements between one and three years were in the areas of housing, 
training and employment.
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